It just may have become more difficult to get negative home care provisions out of - and good home care provisions into - the pending legislation for a Medicare prescription drug bill and other Medicare changes. The Congressional Budget Office says both the House and Senate-passed bills are over the $400 billion, 10-year limit set by President Bush and approved by Congress in the fiscal year 2004 budget. And they're over by tens of billions of dollars. The shortfall may mean legislators will look for cuts to support drug benefit provisions, and home care makes an appealing target. Home health agencies are fighting to get copayments and reductions to payment updates out of the bill while making sure that an add-on for rural home health services and homebound demonstration projects stay in. Durable medical equipment suppliers want to avoid national competitive bidding for a number of items. It now appears that the committee working to reconcile the House and Senate Medicare bills won't reach agreement on provider-specific provisions until after the August recess, when it also will tackle the prescription drug specifics. Agreement on certain regulatory provisions might occur before the end of the month, however, observers say.
In most cases, 100 strips in a three-month period for non-insulin treated beneficiaries, and 100 strips in one month for insulin-treated benes is reasonable and necessary, a CMS official said. But some patients need to test more often, and Medicare will pay for supplies when they do, CMS promised. However, suppliers shouldn't be surprised if the DME regional carriers ask them to show justification for the increased testing need. K0622 through K0626, new codes for bandages, will be added. And the new codes for covered compression stockings, L8110 and L8120, will go on the list, CMS says (see Eli's HCW, Vol. XII, No. 23, p. 183). Finally, three new codes for infusion drugs also will go into effect Oct. 1, CMS says in a separate July 18 memo, B-03-052. Q4075 (Injection, Acyclovir, 5mg), Q4076 (Injection, Dopamine Hydrochloride, 40mg) and Q4077 (Injection, Treprostinil, 1mg) are used in infusion pumps. But DVI still hasn't cleared up the problems that caused auditor Deloitte & Touche to resign in the first place and DVI to miss a Securities and Exchange Commission filing (see Eli's HCW, Vol. XII, No. 25, p. 199). That leaves DVI's health care clients wondering if they can count on future financing, or if the company will go the way of bankrupt National Century Financial Enterprises. Standard & Poor's has left DVI on its watch list for downgrades, reports the Philadelphia Inquirer. LifeCare filed Chapter 11 last November and reported $30 million in annual revenues last year. Tom Robbins, former executive vice president of Apria Healthcare, now helms LifeCare as CEO. Jeremy M. Jones, former Apria chairman and CEO, invested $1 million in LifeCare and now will serve as its chairman, the paper says. The purchase will leave 350 employees in place in Washington, Arizona and California. The bad news: Atlanta-based law firm Chit-wood & Harley has filed a class action securities lawsuit on behalf of Matria shareholders against the company and its officers. It is filed in the U.S. District Court for the Northern District of Georgia. The suit alleges Matria made false and misleading statements in parts of 2001 and 2002 to cover up the company's financial problems.